111 related articles for article (PubMed ID: 30912054)
21. Advances in therapeutic CRISPR/Cas9 genome editing.
Savić N; Schwank G
Transl Res; 2016 Feb; 168():15-21. PubMed ID: 26470680
[TBL] [Abstract][Full Text] [Related]
22. CRISPR-based VEGF suppression using paired guide RNAs for treatment of choroidal neovascularization.
Chung SH; Sin TN; Dang B; Ngo T; Lo T; Lent-Schochet D; Meleppat RK; Zawadzki RJ; Yiu G
Mol Ther Nucleic Acids; 2022 Jun; 28():613-622. PubMed ID: 35614998
[TBL] [Abstract][Full Text] [Related]
23. CRISPR/Cas9 for genome editing: progress, implications and challenges.
Zhang F; Wen Y; Guo X
Hum Mol Genet; 2014 Sep; 23(R1):R40-6. PubMed ID: 24651067
[TBL] [Abstract][Full Text] [Related]
24. [CRISPR-Cas system as molecular scissors for gene therapy].
Heinz GA; Mashreghi MF
Z Rheumatol; 2017 Feb; 76(1):46-49. PubMed ID: 28124743
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic applications of CRISPR RNA-guided genome editing.
Koo T; Kim JS
Brief Funct Genomics; 2017 Jan; 16(1):38-45. PubMed ID: 27562951
[TBL] [Abstract][Full Text] [Related]
26. In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges.
Mout R; Ray M; Lee YW; Scaletti F; Rotello VM
Bioconjug Chem; 2017 Apr; 28(4):880-884. PubMed ID: 28263568
[TBL] [Abstract][Full Text] [Related]
27. The potential application and challenge of powerful CRISPR/Cas9 system in cardiovascular research.
Li Y; Song YH; Liu B; Yu XY
Int J Cardiol; 2017 Jan; 227():191-193. PubMed ID: 27847153
[TBL] [Abstract][Full Text] [Related]
28. Use of CRISPR/Cas9 gene-editing tools for developing models in drug discovery.
Ahmad G; Amiji M
Drug Discov Today; 2018 Mar; 23(3):519-533. PubMed ID: 29326075
[TBL] [Abstract][Full Text] [Related]
29. Analysis of microsatellite instability in CRISPR/Cas9 editing mice.
Huo X; Du Y; Lu J; Guo M; Li Z; Zhang S; Li X; Chen Z; Du X
Mutat Res; 2017 Mar; 797-799():1-6. PubMed ID: 28284774
[TBL] [Abstract][Full Text] [Related]
30. Efficient gene disruption in cultured primary human endothelial cells by CRISPR/Cas9.
Abrahimi P; Chang WG; Kluger MS; Qyang Y; Tellides G; Saltzman WM; Pober JS
Circ Res; 2015 Jul; 117(2):121-8. PubMed ID: 25940550
[TBL] [Abstract][Full Text] [Related]
31. Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease.
Doetschman T; Georgieva T
Circ Res; 2017 Mar; 120(5):876-894. PubMed ID: 28254804
[TBL] [Abstract][Full Text] [Related]
32. Efficient Genome Engineering of a Virulent Klebsiella Bacteriophage Using CRISPR-Cas9.
Shen J; Zhou J; Chen GQ; Xiu ZL
J Virol; 2018 Sep; 92(17):. PubMed ID: 29899105
[No Abstract] [Full Text] [Related]
33. Using CRISPR/Cas9 Technology for Manipulating Cell Death Regulators.
Kueh AJ; Herold MJ
Methods Mol Biol; 2016; 1419():253-64. PubMed ID: 27108444
[TBL] [Abstract][Full Text] [Related]
34. CRISPR-Cas9: a new and promising player in gene therapy.
Xiao-Jie L; Hui-Ying X; Zun-Ping K; Jin-Lian C; Li-Juan J
J Med Genet; 2015 May; 52(5):289-96. PubMed ID: 25713109
[TBL] [Abstract][Full Text] [Related]
35. Factors Impacting Efficacy of AAV-Mediated CRISPR-Based Genome Editing for Treatment of Choroidal Neovascularization.
Chung SH; Mollhoff IN; Nguyen U; Nguyen A; Stucka N; Tieu E; Manna S; Meleppat RK; Zhang P; Nguyen EL; Fong J; Zawadzki R; Yiu G
Mol Ther Methods Clin Dev; 2020 Jun; 17():409-417. PubMed ID: 32128346
[TBL] [Abstract][Full Text] [Related]
36. The CRISPR/Cas9 system: Their delivery, in vivo and ex vivo applications and clinical development by startups.
Song M
Biotechnol Prog; 2017 Jul; 33(4):1035-1045. PubMed ID: 28440027
[TBL] [Abstract][Full Text] [Related]
37. [Advances in application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 system in stem cells research].
Sun SJ; Huo JH; Geng ZJ; Sun XY; Fu XB
Zhonghua Shao Shang Za Zhi; 2018 Apr; 34(4):253-256. PubMed ID: 29690746
[TBL] [Abstract][Full Text] [Related]
38. CRISPR-ERA: a comprehensive design tool for CRISPR-mediated gene editing, repression and activation.
Liu H; Wei Z; Dominguez A; Li Y; Wang X; Qi LS
Bioinformatics; 2015 Nov; 31(22):3676-8. PubMed ID: 26209430
[TBL] [Abstract][Full Text] [Related]
39. Adenovirus-Mediated Somatic Genome Editing of Pten by CRISPR/Cas9 in Mouse Liver in Spite of Cas9-Specific Immune Responses.
Wang D; Mou H; Li S; Li Y; Hough S; Tran K; Li J; Yin H; Anderson DG; Sontheimer EJ; Weng Z; Gao G; Xue W
Hum Gene Ther; 2015 Jul; 26(7):432-42. PubMed ID: 26086867
[TBL] [Abstract][Full Text] [Related]
40. Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing.
Heckl D; Kowalczyk MS; Yudovich D; Belizaire R; Puram RV; McConkey ME; Thielke A; Aster JC; Regev A; Ebert BL
Nat Biotechnol; 2014 Sep; 32(9):941-6. PubMed ID: 24952903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
